Press release
Key Companies Leading Innovation and Growth in the End Stage Renal Disease (ESRD) Drug Market
End Stage Renal Disease (ESRD) Drug Market
Projected Growth and Market Size of the End Stage Renal Disease Drug Market
The ESRD drug market is anticipated to experience rapid growth, reaching a value of $304.07 billion by 2030. This expansion is driven by a healthy compound annual growth rate (CAGR) of 15.5%. Factors such as the advancement in precision medicine, the growing use of homecare dialysis, the integration of artificial intelligence (AI) in patient monitoring, increased funding in ESRD research and development, and rising adoption of combination drug therapies all contribute to this promising trajectory. Key trends shaping the market include personalized drug treatments for ESRD, home-centered dialysis options, telemedicine for chronic kidney disease (CKD) management, innovative drug formulations tackling secondary complications, and the broader acceptance of combination therapies.
Download a free sample of the end stage renal disease (esrd) drug market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR
Leading Companies Steering the End Stage Renal Disease Drug Industry
Several prominent companies dominate the ESRD drug market, including Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, and Merck Co. & KGaA.
In a notable development in May 2024, Vertex Pharmaceuticals, a US biotechnology firm specializing in genetic diseases and immunology, acquired Alpine Immune Sciences for an undisclosed sum. This strategic move was designed to broaden Vertex's renal disease portfolio by acquiring povetacicept - Alpine's lead candidate targeting IgA nephropathy (IgAN), a chronic autoimmune kidney disorder that can progress to ESRD. Additionally, this acquisition integrates Alpine's expertise in protein engineering and immunotherapy. Alpine Immune Sciences is a clinical-stage biotech company focused on engineered immunotherapies, with povetacicept advancing into Phase 3 trials for IgAN.
View the full end stage renal disease (esrd) drug market report:
https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR
Current Trends and Emerging Opportunities in the ESRD Drug Sector
Focus on regulatory approvals is a key strategy among leading ESRD drug manufacturers to boost market revenues. One prime example is Jardiance, a drug aimed at helping patients with type 2 diabetes and reducing cardiovascular risks associated with the disease. In September 2023, Boehringer Ingelheim Pharmaceuticals Inc., a US-based pharmaceutical company, received FDA approval for Jardiance. This drug has been authorized for multiple uses, such as lowering the risk of progression to end-stage kidney disease, cardiovascular death, and hospitalizations among adults with chronic kidney disease who face progression risk. Jardiance also helps reduce the decline in estimated glomerular filtration rate (eGFR) in adults with heart failure. As a sodium-glucose cotransporter 2 (SGLT2) inhibitor, Jardiance is not recommended for patients with type 1 diabetes or those with an eGFR below 20 ml/min/1.73 m2.
Dominant Segments Within the End Stage Renal Disease Drug Market
The ESRD drug market is segmented into various categories for a comprehensive understanding:
1) By Product Type:
- Calcimimetics
- Vitamin D
- Sterols
- Potassium Binders
- Calcium-Based Phosphate Binders
- Other Products
2) By Indication:
- ESRD-Induced Hyperparathyroidism
- ESRD-Induced Hyperphosphatemia
- ESRD-Induced Hyperkaliemia
3) By Distribution Channel:
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
4) By End User:
- Hospitals
- Homecare
- Specialty Clinics
- Other End Users
Within these categories, subsegments include:
- Calcimimetics such as Cinacalcet and Etelcalcetide
- Vitamin D variants like Calcitriol, Doxercalciferol, and Paricalcitol
- Sterols including Ergocalciferol and Cholecalciferol
- Potassium Binders such as Sodium Polystyrene Sulfonate, Patiromer, and Sodium Zirconium Cyclosilicate
- Calcium-Based Phosphate Binders like Calcium Acetate and Calcium Carbonate
- Other products including Iron Supplements and Erythropoiesis-Stimulating Agents
This detailed segmentation highlights the diversity of products and therapeutic targets within the ESRD drug market, reflecting its complexity and scope.
The 2026 edition of our market reports now delivers enhanced analytical coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Key Companies Leading Innovation and Growth in the End Stage Renal Disease (ESRD) Drug Market here
News-ID: 4593744 • Views: …
More Releases from The Business Research Company
Competitive Landscape: Key Market Leaders and New Entrants in the Hair Removal D …
The hair removal devices market is on track for significant expansion, reflecting the growing consumer interest in convenient and effective aesthetic solutions. As technology advances and preferences shift toward home-based and non-invasive treatments, the market is set to experience noteworthy changes in the coming years. Below, we delve into the market's size, key players, emerging trends, and the segments shaping its growth.
Projected Market Size of the Hair Removal Devices Market…
Analysis of Key Market Segments Influencing the Gene Therapy Market
The field of gene therapy is on the verge of remarkable expansion, driven by scientific advancements and growing investments. As innovative techniques and collaborations emerge, this market is set to transform treatments for a variety of genetic conditions. Let's delve into the current market size, key players, emerging trends, and the segments shaping the future of gene therapy.
Projected Growth and Market Size of the Gene Therapy Sector
The gene therapy…
Emerging Growth Patterns Driving Expansion in the H2 Antagonists Market
The H2 antagonists market is set for notable expansion over the coming years, driven by shifting demographics and evolving healthcare practices. This sector plays a crucial role in managing acid-related disorders, and with increasing consumer access to medications, the market's trajectory looks promising. Below, we explore the market size projections, key players, emerging trends, and how the market is segmented by type, application, and region.
Anticipated Growth Path for the H2…
Leading Companies Fueling Innovation and Growth in the Gene Expression Market
The gene expression market is on the cusp of remarkable expansion, driven by technological advancements and growing applications across various fields. As new innovations emerge and investments increase, this sector is positioned to experience significant growth and transformation in the coming years. Let's explore the market's size projections, key players, prevailing trends, and the primary segments shaping its trajectory.
Projected Growth Trajectory of the Gene Expression Market
The gene expression market…
More Releases for ESRD
Driving End Stage Renal Disease (ESRD) Drug Market Growth in 2025: The Role of T …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
End Stage Renal Disease (ESRD) Drug Market Size Growth Forecast: What to Expect by 2025?
The market size for drugs treating end stage renal disease (ESRD) has seen a quick expansion in the recent past. The market, which was valued at $131.41 billion in 2024, is forecasted to reach $149.88 billion in 2025, displaying…
End Stage Renal Disease (ESRD) Drug Industry Report 2025-2034: Market Dynamics, …
The End Stage Renal Disease (ESRD) Drug Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current End Stage Renal Disease (ESRD) Drug Market Size and Its Estimated Growth Rate?
The market size for end-stage renal disease (ESRD) medications has witnessed a rapid upsurge…
End Stage Renal Disease (ESRD) Drug Market Report 2024 - End Stage Renal Disease …
"The Business Research Company recently released a comprehensive report on the Global End Stage Renal Disease (ESRD) Drug Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The…
End-Stage Renal Disease (ESRD) Market Share, Revenue, Prospects and Forecast 202 …
In recent years, the global End-Stage Renal Disease (ESRD) Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on End-Stage Renal Disease (ESRD) Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business…
End Stage Renal Disease (ESRD) Drug Market Size, Share, and Scope 2033
The new report published by The Business Research Company, titled ""End Stage Renal Disease (ESRD) Drug Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the end stage renal disease (esrd) drug market size has grown rapidly in recent years.…
End Stage Renal Disease (ESRD) Drug Market 2024-2033: Trends, Analysis & Growth …
The end stage renal disease (esrd) drug market size has grown rapidly in recent years. It will grow from $116.32 billion in 2023 to $132.86 billion in 2024 at a compound annual growth rate (CAGR) of 14.2%. The growth in the historic period can be attributed to increasing incidence of end stage renal disease, growing aging population, improved access to healthcare services, government initiatives and policies, increasing adoption…
